title: Long-term renal prognosis of IgA nephropathy with therapeutic trend shifts.
abstract: OBJECTIVE
  We compared the effect of treatments in the long-term renal survival of IgA nephropathy.
  
  
  METHODS
  One hundred and fourteen patients with biopsy-proven IgA nephropathy were retrospectively divided into 4 groups, reflecting shifts in treatment trends from 1985 to 2005: patients without treatment (no treatment group; n=36), patients treated only with anti-platelet drugs (anti-platelet group; n=12), those treated mainly with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) (ACEI/ARB group; n =29), and prednisolone-treated patients (PSL group; n =37).
  
  
  RESULTS
  Baseline blood pressure, serum creatinine and renal histological findings were similar among the 4 groups; however, the urinary protein level was significantly severer in the PSL group. After a mean follow-up of 7.0+/-0.5 years, end-stage renal disease occurred in 11 patients (31%) in the no treatment group, 5 patients (42%) in the anti-platelet group and 3 patients (8%) in the PSL group, but in only 1 patient (3%) in the ACEI/ARB group. Kaplan-Meier renal survival after 20 years was significantly better in the ACEI/ARB group than in the anti-platelet group or in the no treatment group (p<0.05). The patients that reached complete remission (CR) by steroid therapy showed less baseline urinary protein and milder histological lesions than those who did not reach CR. The non-CR group showed increases in serum creatinine and eGFR reduction rate.
  
  
  CONCLUSIONS
  Treatment with renin-angiotensin system inhibitors showed the greatest improvement of 20-year renal survival in IgA nephropathy patients. Steroid therapy achieved complete remission in some early-stage cases.
authors.affiliation: Department of Internal Medicine, University of Tokyo, Tokyo.
authors.forename: Kensuke
authors.initials: K
authors.lastname: Asaba
authors.forename: Akihiro
authors.initials: A
authors.lastname: Tojo
authors.forename: Maristela Lika
authors.initials: ML
authors.lastname: Onozato
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kinugasa
authors.forename: Hiroki
authors.initials: H
authors.lastname: Miyazaki
authors.forename: Kazuhisa
authors.initials: K
authors.lastname: Miyashita
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Uehara
authors.forename: Yasunobu
authors.initials: Y
authors.lastname: Hirata
authors.forename: Kenjiro
authors.initials: K
authors.lastname: Kimura
authors.forename: Atsuo
authors.initials: A
authors.lastname: Goto
authors.forename: Masao
authors.initials: M
authors.lastname: Omata
authors.forename: Toshiro
authors.initials: T
authors.lastname: Fujita
mesh_terms: D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D005922:Glomerulonephritis, IGA / Q000175:diagnosis* / Q000401:mortality* / Q000628:therapy; D006801:Humans; D008297:Male; D011379:Prognosis; D011945:Receptors, Angiotensin / Q000627:therapeutic use; D012189:Retrospective Studies; D015996:Survival Rate / Q000639:trends; D013997:Time Factors
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D011945:Receptors, Angiotensin